Navigation Links
RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
Date:2/19/2008

- Natural Supplement for Attention-Deficit Hyperactivity Disorder in

Children Fulfills Growing Need Throughout Asia -

NEW HAVEN, Conn. and KORTRIJK, Belgium, Feb. 19 /PRNewswire/ -- RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental(R) throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.

"There is a great opportunity for Attental throughout Asia where parents prefer giving their children natural products versus prescription drugs," said Joos Horsten, Executive Chairman and Chief Executive Officer of RHEI. "There has been a growing awareness of ADHD in Asia as a more western diet and lifestyle is adopted. In addition, there are now several government programs in place to train doctors and teachers to better identify and treat children suffering from ADHD. RHEI will utilize its experience in pharmaceutical marketing and its network of contacts, particularly within the pediatric community, to bring this important natural remedy to the Asian market."

Attental has been proven in a randomized, double-blind, placebo controlled clinical trial to better overall motor performance and improve reading and spelling in children. The clinical trial demonstrated a significant improvement in the Conners' Teaching Rating Scale-L (CTRS-L) of 59 items describing different aspects of child behavior, as well as in the Child Behavior Checklist (CBCL) -- standard evaluation methods for ADHD.

"RHEI's approach which includes a hospital-based sales force in China that understands the scientific aspects of ADHD and can communicate the benefits of Attental, combined with their experience in direct to consumer and pharmacy-based marketing is the perfect partner to market and distribute Attental throughout Asia," said Curd Devos, Chief Executive Officer of MethaPharma. "We see tremendous growth potential for a product like Attental in the Asian market. It is estimated that 19.8 million children in China alone suffer from ADHD and as awareness of the disorder grows, we believe that by working with RHEI we will be well positioned to offer children and their parents a natural product that has been clinically proven to improve the behavior associated with ADHD."

About MethaPharma

MethaPharma was founded in 2003 and develops high quality food supplements (nutraceuticals). MethaPharma is present in the Belgian market since 2005 with glucosamine-products such as Osteoplus, Glucactiv and Chondractiv for a fluid articulation. After some time, Benypro was launched for the prostate and Attental for ADHD (Attention Deficit Hyperactivity Disorder), dyslexia and concentration problems. MethaPharma is now part of the Vemedia group. For more information see http://www.vemediapharma.com.

About RHEI Pharmaceuticals

RHEI Pharmaceuticals is a venture backed specialty pharmaceutical company with operations in Belgium, the U.S. and China that acquires, licenses, develops and commercializes in China proprietary drug therapies based upon the unmet needs of the emerging China pharmaceuticals market. RHEI leverages its proprietary and extensive network of experienced clinical development and regulatory professionals in China to expedite approvals for pharmaceuticals new to the China market. RHEI's growing sales and marketing capabilities then provide broad patient access in China to these new and critically necessary therapeutics. RHEI specializes in hospital-based proprietary products with a therapeutic focus on urgent unmet needs in the areas of cancer, cardiovascular disease, diabetes, neurology, and other life threatening conditions.


'/>"/>
SOURCE RHEI Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
2. NUCRYST Pharmaceuticals announces year-end results
3. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
6. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
7. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
8. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
9. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology: